As @irir2 pointed out, we now have FDA approval for FebriDx, that was what caused the jump in the share price after the CR was completed.
The share price has not sustained the higher share price though as the market is waiting to see what that means for LDX in terms of revenue and cash burn.
We do still have other propriety tests in the pipeline which can add to the prospects for LDX, especially if FebriDx can take them into cash flow positive territory:
ViraDx: Test to confirm COVID-19 or influenza infection is present
UriDx: Test to confirm thepresence of a UTI
SepsiDx: Test to confirm blood stream infections
As @irir2 pointed out, we now have FDA approval for FebriDx,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $24.66K | 945.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 315442 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 1463859 | 3 |
View Market Depth
| Last trade - 15.59pm 24/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |